Stockscreener 앱 받기
0.7147
1.23%
-0.0089
Lexicon Pharmaceuticals Inc 주식(LXRX)의 최신 뉴스
Lexicon Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter for Zynquista? (sotagliflozin) - Marketscreener.com
Stocks to Watch: Rumble, Lexicon Pharmaceuticals - MarketWatch
FDA rejects Lexicon's Zynquista for diabetes, kidney disease - Seeking Alpha
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) - The Manila Times
Lexicon Pharma Receives FDA Rejection for Diabetes Drug Zynquista, Shifts Focus to Pain Treatment Pipeline - StockTitan
Lexicon Pharmaceuticals (LXRX) Stock Declines Amid Biotech Secto - GuruFocus.com
Point72 Asset Management L.P. Sells 2,891,141 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - MarketBeat
Fmr LLC Has $78.29 Million Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - MarketBeat
Lexicon Pharmaceuticals (LXRX) Stock Dips Amid Market Volatility - GuruFocus.com
Lexicon Pharmaceuticals stock hits 52-week low at $0.73 By Investing.com - Investing.com South Africa
Lexicon Pharmaceuticals stock hits 52-week low at $0.73 - Investing.com India
Braidwell LP Sells 7,493,366 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - MarketBeat
Lexicon completes subject enrolment for DPNP trial of LX9211 - Clinical Trials Arena
2 Generic Drug Stocks Ready to Surge in 2025 - Benzinga
The Escalator: Lexicon Pharmaceuticals, Reckitt, NIH and more - MM+M Online
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) - The Manila Times
Lexicon Pharma Hits 120% Enrollment Target in Key Pain Drug Trial, Ahead of Schedule | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals to Participate in December Investor Conferences - The Manila Times
Lexicon Pharmaceuticals CEO to Present at Two Major Healthcare Conferences in December | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals shares target cut, retains buy rating on FDA letter - Investing.com UK
Lexicon pivots back to pipeline after FDA rejection - The Pharma Letter
Lexicon Pharmaceuticals (NASDAQ:LXRX) Receives "Hold" Rating from Needham & Company LLC - MarketBeat
Lexicon Pharmaceuticals to cut 60% of workforce By Investing.com - Investing.com South Africa
Lexicon Pharmaceuticals to cut 60% of workforce - Investing.com India
Lexicon Cuts Commercial Operation, Focuses On R&D After FDA Letdown - Citeline News & Insights
Diabetes Endpoints: A1C Reduction Is ‘Still Enough,’ Just Not For Lexicon’s Sotagliflozin, US FDA Says - Citeline
Lexicon to disband sales team, lay off 60% of staff - BioPharma Dive
Lexicon Pharmaceuticals to lay off 60% of workforce after FDA setback - Reuters.com
Lexicon Pharmaceuticals to Slash 60% of Jobs, Close Commercial Operations as Part of Reorganization - MarketWatch
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA - The Manila Times
Lexicon Pharma (LXRX) to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA - StreetInsider.com
Lexicon Pharma Cuts 60% of Workforce, Saves $140M Amid FDA Setback for Zynquista | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals appoints Ivan Cheung to board By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals (LXRX) Stock Plummets Amidst Market Acti - GuruFocus.com
Lexicon Appoints Ivan H. Cheung to Board of Directors - The Manila Times
Lexicon Appoints Ivan Cheung to Board of Directors - citybiz
Lexicon Pharmaceuticals appoints Ivan Cheung to board - Investing.com India
Lexicon Pharma (LXRX) Appoints Ivan H. Cheung to its Board - StreetInsider.com
Lexicon Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week - Yahoo Finance
Leerink Partnrs Has Positive Estimate for LXRX Q4 Earnings - MarketBeat
Lexicon Pharmaceuticals stock hits 52-week low at $1 - Investing.com India
What is HC Wainwright's Forecast for LXRX FY2024 Earnings? - MarketBeat
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago - The Manila Times
Lexicon's Sotagliflozin Shows Strong Benefits Across All Heart Failure Stages in New Data | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2024 Earnings Call Transcript - Insider Monkey
2.88%
2.65%
자본화:
|
볼륨(24시간):